Celsion Corp (CLSN) 1.40 $CLSN
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting
PR Newswire - Tue May 24, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.40 (-0.02)
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Mon May 16, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based immunotherapy.
CLSN: 1.40 (-0.02)
Should You Buy Celsion (CLSN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:57AM CDT
Celsion (CLSN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
CLSN: 1.40 (-0.02)
Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016
PR Newswire - Mon May 09, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, May 16, 2016. To participate in the call, interested parties may dial 1-888-359-3624 (Toll-Free/North America) or 1-719-457-2085 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2016 Earnings Call (Conference Code: 7064110) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
CLSN: 1.40 (-0.02)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 32.45 (-1.11), CLSN: 1.40 (-0.02), JAZZ: 150.76 (-5.26)
ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:14AM CDT
Our proven model does not conclusively show that ARIAD (ARIA) is likely to beat estimates this quarter given its Earnings ESP of 0.00% and Zacks Rank #5 (Strong Sell).
CLSN: 1.40 (-0.02), JAZZ: 150.76 (-5.26), ARIA: 8.27 (-0.15), CHMA: 2.91 (-0.23)
Penumbra (PEN): What Will Q1 Earnings Release Unveil?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:53AM CDT
Penumbra, Inc. (PEN) is expected to report its first-quarter 2016 financial numbers on May 9, after the market closes.
CLSN: 1.40 (-0.02), QSII: 12.44 (+0.08), PEN: 60.12 (-0.85), CHMA: 2.91 (-0.23)
Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study
PR Newswire - Mon May 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. In the first three patients dosed, GEN-1 plus standard chemotherapy produced excellent results, with no dose limiting toxicities and highly promising efficacy signals leading to successful surgical outcomes. The three patients were treated at the University of Alabama at Birmingham.
CLSN: 1.40 (-0.02)
Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China
PR Newswire - Tue Apr 26, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat newly diagnosed patients with primary liver cancer, also known as hepatocellular carcinoma (HCC).
CLSN: 1.40 (-0.02)
Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil®
PR Newswire - Tue Apr 19, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® and Doxil® was presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. The full poster presentation can be found on Celsion's website at www.celsion.com.
CLSN: 1.40 (-0.02)
Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer
PR Newswire - Tue Apr 12, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian cancer will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held in New Orleans from April 16-20, 2016. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.40 (-0.02)
Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update
PR Newswire - Wed Mar 30, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The Company's lead program is ThermoDox® which is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The Company's immunotherapy program consists of GEN-1 and is currently in Phase I development for the localized treatment of ovarian cancer.
CLSN: 1.40 (-0.02)
Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016
PR Newswire - Wed Mar 23, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Wednesday, March 30, 2016. To participate in the call, interested parties may dial 1-800-505-9587 (Toll-Free/North America) or 1-416-204-9524 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2015 Earnings Call (Conference Code: 4103364) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com.
CLSN: 1.40 (-0.02)
Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® at the AACR Annual Meeting 2016
PR Newswire - Wed Mar 16, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that its preclinical data for GEN-1 in combination with Avastin® and Doxil® for the treatment of ovarian cancer will be presented at the upcoming AACR Annual Meeting 2016 in New Orleans. The presentation will be held on Monday, April 18, 2016 (1:00 pm to 5:00 pm) and will summarize results from preclinical studies demonstrating significant synergistic anti-cancer effects when GEN-1 is combined with Avastin® and Doxil®, a current Standard of Care (SoC) for platinum resistant ovarian cancer patients. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. These data will be used by the Company to support a comprehensive IND protocol filing for a Phase I/II clinical trial evaluating the combination in recurrent ovarian cancer later this year.
CLSN: 1.40 (-0.02)
Celsion Corporation Announces Launch of the OPTIMA Study in China
PR Newswire - Mon Mar 07, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced the launch of the OPTIMA Study in China. The Company held an Investigators' Meeting for the OPTIMA Study on March 5, 2016 in Shanghai, China. Professor Ronnie T.P. Poon, MD, MBBS, MS, PhD, FRCS (Edin), FACS, Medical Director at the Hong Kong Integrated Oncology Center, Honorary Professor of Surgery at the University of Hong Kong Queen Mary Hospital, and member of the International Liver Cancer Association (ILCA) Governing Board provided the Keynote Address entitled "Treatment Strategies for Early/Intermediate HCC." Professor Poon discussed strategies for treating different stages of primary liver cancer, also known as hepatocellular carcinoma (HCC); including intermediate stage HCC which has been previously thought to be incurable. New treatment strategies, most notably an optimized RFA procedure with the investigational drug, ThermoDox®, show clear promise as a potential cure for intermediate HCC in the years ahead. Investigators and their staff from 20 sites in mainland China and Hong Kong were in attendance. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat newly diagnosed patients with HCC.
CLSN: 1.40 (-0.02)
Global Peritoneal Cancer Therapeutics Pipeline Review H2 2015
M2 - Thu Jan 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dwpnp/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peritoneal Cancer Overview - Therapeutics Development - Pipeline Products for Peritoneal Cancer - Overview - Pipeline Products for Peritoneal Cancer - Comparative Analysis - Peritoneal Cancer - Therapeutics under Development by Companies - Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes - Peritoneal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peritoneal Cancer - Products under Development by Companies - Peritoneal Cancer - Products under Investigation by Universities/Institutes - Peritoneal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Advanced Accelerator Applications SA - Amgen Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Atara Biotherapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Beth Israel Deaconess Medical Center, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Celldex Therapeutics, Inc. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Corcept Therapeutics Incorporated - Critical Outcome Technologies Inc. - CritiTech, Inc. - CTI BioPharma Corp. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Galena Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9d...eal_cancer
CERU: 2.32 (+0.02), CLDX: 4.12 (-0.20), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), ATRA: 19.53 (-0.57), CTIC: 0.43 (-0.01), CLBS: 0.53 (unch), AAAP: 31.26 (-0.67), CLSN: 1.40 (-0.02), CLVS: 14.11 (-1.12), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), ABBV: 61.00 (+0.25), CORT: 5.60 (+0.13), EXEL: 7.38 (+0.01), XLRN: 35.44 (+0.94), ARRY: 3.51 (-0.01)
Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer
PR Newswire - Thu Jan 07, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant ovarian cancer. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The new data demonstrate that intraperitoneally-administered GEN-1 produces an immunologically distinct IL-12 protein that is localized at the tumor site and lasts for up to one week after a single treatment. Furthermore, concomitant increases in IFN- and TNF- a indicate that the IL-12 produced following treatment with GEN-1 treatment is immunologically active. Celsion Corporation is a fully integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases.
CLSN: 1.40 (-0.02)
Pulmonary Hypertension - Pipeline Review 2015
M2 - Wed Jan 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c3rcb/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Complexa, Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Insmed Incorporated - Kowa Company, Ltd. - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - (20 Others) For more information visit http://www.researchandmarkets.com/research/6c3rcb/pulmonary
CYTK: 8.21 (-0.09), INSM: 10.88 (-0.14), CLSN: 1.40 (-0.02), ASND: 13.46 (-0.13), GILD: 84.45 (-1.32), LLY: 73.95 (-0.48), ARNA: 1.99 (-0.07)
Exelixis Reveals Data on Cabozantinib for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:00PM CST
Exelixis, Inc. (EXEL) announced positive data from the phase III trial, METEOR, which compared cabozantinib to Afinitor in patients suffering from renal cell carcinoma (RCC).
CLSN: 1.40 (-0.02), JUNO: 42.98 (-2.55), BXLT: 46.02 (-0.18), EXEL: 7.38 (+0.01)
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting
PR Newswire - Tue May 24, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.40 (-0.02)
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Mon May 16, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based immunotherapy.
CLSN: 1.40 (-0.02)
Should You Buy Celsion (CLSN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:57AM CDT
Celsion (CLSN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
CLSN: 1.40 (-0.02)
Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016
PR Newswire - Mon May 09, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, May 16, 2016. To participate in the call, interested parties may dial 1-888-359-3624 (Toll-Free/North America) or 1-719-457-2085 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2016 Earnings Call (Conference Code: 7064110) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
CLSN: 1.40 (-0.02)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 32.45 (-1.11), CLSN: 1.40 (-0.02), JAZZ: 150.76 (-5.26)
ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:14AM CDT
Our proven model does not conclusively show that ARIAD (ARIA) is likely to beat estimates this quarter given its Earnings ESP of 0.00% and Zacks Rank #5 (Strong Sell).
CLSN: 1.40 (-0.02), JAZZ: 150.76 (-5.26), ARIA: 8.27 (-0.15), CHMA: 2.91 (-0.23)
Penumbra (PEN): What Will Q1 Earnings Release Unveil?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:53AM CDT
Penumbra, Inc. (PEN) is expected to report its first-quarter 2016 financial numbers on May 9, after the market closes.
CLSN: 1.40 (-0.02), QSII: 12.44 (+0.08), PEN: 60.12 (-0.85), CHMA: 2.91 (-0.23)
Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study
PR Newswire - Mon May 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. In the first three patients dosed, GEN-1 plus standard chemotherapy produced excellent results, with no dose limiting toxicities and highly promising efficacy signals leading to successful surgical outcomes. The three patients were treated at the University of Alabama at Birmingham.
CLSN: 1.40 (-0.02)
Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China
PR Newswire - Tue Apr 26, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat newly diagnosed patients with primary liver cancer, also known as hepatocellular carcinoma (HCC).
CLSN: 1.40 (-0.02)
Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil®
PR Newswire - Tue Apr 19, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® and Doxil® was presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. The full poster presentation can be found on Celsion's website at www.celsion.com.
CLSN: 1.40 (-0.02)
Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer
PR Newswire - Tue Apr 12, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian cancer will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held in New Orleans from April 16-20, 2016. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.40 (-0.02)
Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update
PR Newswire - Wed Mar 30, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The Company's lead program is ThermoDox® which is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The Company's immunotherapy program consists of GEN-1 and is currently in Phase I development for the localized treatment of ovarian cancer.
CLSN: 1.40 (-0.02)
Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016
PR Newswire - Wed Mar 23, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Wednesday, March 30, 2016. To participate in the call, interested parties may dial 1-800-505-9587 (Toll-Free/North America) or 1-416-204-9524 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2015 Earnings Call (Conference Code: 4103364) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com.
CLSN: 1.40 (-0.02)
Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® at the AACR Annual Meeting 2016
PR Newswire - Wed Mar 16, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that its preclinical data for GEN-1 in combination with Avastin® and Doxil® for the treatment of ovarian cancer will be presented at the upcoming AACR Annual Meeting 2016 in New Orleans. The presentation will be held on Monday, April 18, 2016 (1:00 pm to 5:00 pm) and will summarize results from preclinical studies demonstrating significant synergistic anti-cancer effects when GEN-1 is combined with Avastin® and Doxil®, a current Standard of Care (SoC) for platinum resistant ovarian cancer patients. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. These data will be used by the Company to support a comprehensive IND protocol filing for a Phase I/II clinical trial evaluating the combination in recurrent ovarian cancer later this year.
CLSN: 1.40 (-0.02)
Celsion Corporation Announces Launch of the OPTIMA Study in China
PR Newswire - Mon Mar 07, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced the launch of the OPTIMA Study in China. The Company held an Investigators' Meeting for the OPTIMA Study on March 5, 2016 in Shanghai, China. Professor Ronnie T.P. Poon, MD, MBBS, MS, PhD, FRCS (Edin), FACS, Medical Director at the Hong Kong Integrated Oncology Center, Honorary Professor of Surgery at the University of Hong Kong Queen Mary Hospital, and member of the International Liver Cancer Association (ILCA) Governing Board provided the Keynote Address entitled "Treatment Strategies for Early/Intermediate HCC." Professor Poon discussed strategies for treating different stages of primary liver cancer, also known as hepatocellular carcinoma (HCC); including intermediate stage HCC which has been previously thought to be incurable. New treatment strategies, most notably an optimized RFA procedure with the investigational drug, ThermoDox®, show clear promise as a potential cure for intermediate HCC in the years ahead. Investigators and their staff from 20 sites in mainland China and Hong Kong were in attendance. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat newly diagnosed patients with HCC.
CLSN: 1.40 (-0.02)
Global Peritoneal Cancer Therapeutics Pipeline Review H2 2015
M2 - Thu Jan 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dwpnp/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peritoneal Cancer Overview - Therapeutics Development - Pipeline Products for Peritoneal Cancer - Overview - Pipeline Products for Peritoneal Cancer - Comparative Analysis - Peritoneal Cancer - Therapeutics under Development by Companies - Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes - Peritoneal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peritoneal Cancer - Products under Development by Companies - Peritoneal Cancer - Products under Investigation by Universities/Institutes - Peritoneal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Advanced Accelerator Applications SA - Amgen Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Atara Biotherapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Beth Israel Deaconess Medical Center, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Celldex Therapeutics, Inc. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Corcept Therapeutics Incorporated - Critical Outcome Technologies Inc. - CritiTech, Inc. - CTI BioPharma Corp. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Galena Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9d...eal_cancer
CERU: 2.32 (+0.02), CLDX: 4.12 (-0.20), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), ATRA: 19.53 (-0.57), CTIC: 0.43 (-0.01), CLBS: 0.53 (unch), AAAP: 31.26 (-0.67), CLSN: 1.40 (-0.02), CLVS: 14.11 (-1.12), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), ABBV: 61.00 (+0.25), CORT: 5.60 (+0.13), EXEL: 7.38 (+0.01), XLRN: 35.44 (+0.94), ARRY: 3.51 (-0.01)
Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer
PR Newswire - Thu Jan 07, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant ovarian cancer. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The new data demonstrate that intraperitoneally-administered GEN-1 produces an immunologically distinct IL-12 protein that is localized at the tumor site and lasts for up to one week after a single treatment. Furthermore, concomitant increases in IFN- and TNF- a indicate that the IL-12 produced following treatment with GEN-1 treatment is immunologically active. Celsion Corporation is a fully integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases.
CLSN: 1.40 (-0.02)
Pulmonary Hypertension - Pipeline Review 2015
M2 - Wed Jan 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c3rcb/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Complexa, Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Insmed Incorporated - Kowa Company, Ltd. - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - (20 Others) For more information visit http://www.researchandmarkets.com/research/6c3rcb/pulmonary
CYTK: 8.21 (-0.09), INSM: 10.88 (-0.14), CLSN: 1.40 (-0.02), ASND: 13.46 (-0.13), GILD: 84.45 (-1.32), LLY: 73.95 (-0.48), ARNA: 1.99 (-0.07)
Exelixis Reveals Data on Cabozantinib for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:00PM CST
Exelixis, Inc. (EXEL) announced positive data from the phase III trial, METEOR, which compared cabozantinib to Afinitor in patients suffering from renal cell carcinoma (RCC).
CLSN: 1.40 (-0.02), JUNO: 42.98 (-2.55), BXLT: 46.02 (-0.18), EXEL: 7.38 (+0.01)
